Historic 21.1-Month Median Overall Survival Reported at ESMO
Definitive Phase 3 clinical data presented Saturday at the European Society for Medical Oncology (ESMO) Congress in Madrid and featured in the New England Journal of Medicine delivered a historic victory for thoracic oncology. In a trial evaluating 563 patients presenting with extensive-stage small cell lung cancer (ES-SCLC) whose tumors had stabilized post-chemotherapy, combining Amgen's bispecific antibody Imdelltra (tarlatamab) with AstraZeneca's Imfinzi (durvalumab) yielded a statistically striking 58% reduction in the hazard of mortality.
Patients receiving the investigational combination survived for a median of 21.1 months, radically outpacing the 12.7-month median survival recorded among those maintained solely on standard-of-care Imfinzi. At the 12-month follow-up milestone, 80% of individuals in the dual-therapy cohort remained alive, compared with 53% administered immunotherapy monotherapy.
If you give Imdelltra earlier and earlier, you get bigger clinical benefit; the results are unprecedented in advancing the treatment of extensive-stage small cell lung cancer.








